Cartesian Therapeutics, Inc.RNACNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank73
3Y CAGR+75.6%
5Y CAGR+0.8%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+75.6%/yr
vs -1.3%/yr prior
5Y CAGR
+0.8%/yr
Recent acceleration
Acceleration
+76.9pp
Accelerating
Percentile
P73
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 28.66% |
| 2024 | -36.70% |
| 2023 | -1.54% |
| 2022 | 5.30% |
| 2021 | 26.11% |
| 2020 | 27.52% |
| 2019 | -10.37% |
| 2018 | 5.58% |
| 2017 | 52.06% |
| 2016 | 29.25% |